Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Ascend Communications (ASND) -- Ignore unavailable to you. Want to Upgrade?

To: Mighty Mizzou who wrote (58040)	12/10/1998 4:30:00 PM
From: Mighty Mizzou	Respond to of 61433

Another exciting day on the ASND board! Oh well, -1 on low volume and NO STRATUS NEWS (MORY!) isnt that bad I guess. At least we didnt get a 25% price target upgrade and only finished up 7/16, or in the case of NN right back to where they were in January, sheesh! Burned a whole year with nothing to show for it... ASND YTD +200%, NN YTD 0% zero zip nada nyet zilch goose egg. Now that sucks! GO ASND!!!!!!!

To: Mighty Mizzou who wrote (58040)	12/10/1998 5:19:00 PM
From: Hagar	Respond to of 61433

Now if these guys think they are going to pull one over Bell Labs using only software, then I have to hand it to them. Personally I think it is an expensive ($20m) joke. But what the heck, if VC's are going to throw this kind of $$$ at anything internet related I would do the same thing! I don't quite understand this. If this is in reference to the product that Sycamore intends to build I think its way of base.

To: Mighty Mizzou who wrote (58040)	12/10/1998 10:26:00 PM
From: Kent Rattey	Read Replies (2) \| Respond to of 61433

BRUCE SACHS NAMED TO VERTEX BOARD OF DIRECTORS CAMBRIDGE, Mass., Dec. 10 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that Mr. Bruce Sachs has been named to the Company's Board of Directors. Mr. Sachs currently leads the Carrier Signaling and Management business unit at Ascend Communications, following Ascend's recent acquisition of Stratus Computer, Inc. Prior to the acquisition, Mr. Sachs served as President and CEO of Stratus, a global fault- tolerant computer solutions company with 2,300 employees. "Bruce Sachs brings a wealth of entrepreneurial and operational experience to Vertex's board," said Dr. Joshua Boger, Chairman, President, and CEO of Vertex. "Bruce has an impressive track record building and leading several highly successful technology companies within a fast-paced, high-growth business environment. Vertex will benefit from Bruce's experience as we navigate multiple innovative research and development programs through to the marketplace." From 1995 to 1997 Mr. Sachs served as Executive Vice President/General Manager of the Internet Telecom Business Group at Bay Networks, managing the $800 million Internet/Telco division and formulating Bay Networks' strategy in the Internet market segment. From 1993 to 1995, Mr. Sachs served as President and Chief Executive Officer at remote access provider Xylogics, Inc., which was acquired by Bay Networks in 1995. Mr. Sachs held various management positions at Xylogics beginning in 1989. He holds a Master's Degree in Business Administration from Northeastern University, a Master's Degree in Electrical Engineering (MEEE) from Cornell University, and a BSEE from Bucknell University. Mr. Sachs, 38, also serves on the board of the Media 100 Corporation. Mr. Sachs joins Dr. Joshua Boger, Dr. Barry Bloom, Dr. Roger Brimblecombe, Mr. Donald Conklin, Mr. William Helman, Dr. Charles Sanders, and Ms. Elaine Ullian on Vertex's Board. Vertex Pharmaceuticals Incorporated is engaged in the discovery, development and commercialization of novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company is a leader in the use of structure-based drug design, an approach to drug discovery that integrates advanced biology, biophysics and chemistry. The Company is concentrating on the discovery and development of drugs for the treatment of viral diseases, multidrug resistance in cancer, autoimmune and inflammatory diseases, and neurodegenerative diseases. SOURCE Vertex Pharmaceuticals Incorporated